Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks

Data ReadoutpositiveTazbentetolPositive

AI Analysis

Summary

Spinogenix reported positive data on Tazbentetol, a first-in-class oral investigational therapy for Alzheimer's disease, showing favorable safety and durable therapeutic benefits in patients treated for up to 84 weeks. Clinical case study presented at AAIC highlighted caregiver-reported rapid cognitive improvement with supporting clinical outcomes.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Demonstrated favorable safety profile and durable therapeutic benefits in Alzheimer's patients treated for up to 84 weeks

Importance:6/10

Sentiment:

0.75

Alzheimer's diseaseclinical datasafety profileoral therapysynaptic regenerationAAIC conference

Related Companies

$TRAX $RTSL

Read the original article

Published by PR Newswire Biotech on July 14, 2026 5:56 PM

Read Original